AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 JUL 9 - (NewsRx.com & NewsRx.net) -- Meridian Bioscience, Inc., (VIVO) announced the signing of its second biopharmaceutical manufacturing agreement for the company's life-science production facility located at Viral Antigens, Inc., Memphis, Tennesee (VAI), a wholly owned subsidiary.
Hawaii Biotech, Inc., has selected VAI to manufacture and supply bulk polyvalent recombinant subunit vaccine for dengue virus 1-4.
The bulk vaccine for human clinical studies will be produced in VAI's new facility designed for the production of recombinant proteins and antibodies for use in therapeutic agents and vaccines.
Hawaii Biotech has developed its dengue vaccine using proprietary technology based on the production of recombinant antigens from the Drosophila cell expression system. The vaccine has been developed in order to confer protective immunity in humans to all four dengue viruses simultaneously. Any of the four viruses can cause dengue fever; however, immunity to less than all four increases the ...